ENGN
enGene Holdings Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website engene.com
- Employees(FY) 31
- ISIN CA29286M1059
Performance
-8.68%
1W
-11.84%
1M
+91.05%
3M
+52.84%
6M
+57.31%
YTD
+37.5%
1Y
Profile
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Technical Analysis of ENGN 2024-05-03
Overview:
In analyzing the technical indicators for ENGN over the last 5 days, we will delve into the trends, momentum, volatility, and volume aspects to provide a comprehensive outlook on the possible stock price movement. By examining key indicators such as moving averages, MACD, RSI, Bollinger Bands, and OBV, we aim to offer valuable insights...
Recent News & Updates
- 2024-05-02 16:05
- 2024-05-02 04:05
- 2024-04-23 06:56
Daily – Vickers Top Buyers & Sellers for 04/23/2024(Argus Research)
- 2024-04-09 08:00
- 2024-04-08 20:56
/C O R R E C T I O N -- enGene Inc./(Prnewswire)
- 2024-04-08 20:00
- 2024-03-11 16:05
- 2024-03-11 05:16
- 2024-03-05 07:00
- 2024-03-04 18:00
- 2024-02-14 06:50
- 2024-02-14 06:45
enGene Announces Leadership Succession Plan(PR Newswire)
- 2024-02-13 17:50
- 2024-02-13 17:45
enGene Announces Leadership Succession Plan(Prnewswire)
- 2024-01-30 07:00
- 2024-01-29 18:00
- 2024-01-29 07:00
- 2024-01-28 18:00
- 2023-12-22 17:00
- 2023-12-22 04:00
- 2023-12-19 07:00
- 2023-12-18 18:00
- 2023-11-28 18:00
- 2023-11-12 20:55
- 2023-11-01 19:00
- 2023-10-31 19:30
Page 1 of 1
previousnext